Top Chartbuster Stocks In Trade Today | What's The Buzz In Manappuram Finance | Stocks In News
Looks like ashirwad IPO will come in July
Something is cooking
Cup and handle
Momentum
Twice traded with big volumes in last 2 weeks
Top Chartbuster Stocks In Trade Today | What's The Buzz In Manappuram Finance | Stocks In News
Looks like ashirwad IPO will come in July
Something is cooking
Cup and handle
Momentum
Twice traded with big volumes in last 2 weeks
On the top right, a link for polymer prices is given, under that you will get all the product list which come under polymers.
Polymers per se is a very huge category and each category has various different grades.
Shalby Ltd -
Q1 FY 25 concall and results highlights -
Revenues - 288 vs 240 cr, up 20 pc
EBITDA - 55 vs 47 cr, up 15 pc
PAT - 15 vs 20 cr ( due higher Interest and Depreciation costs + increased tax rate )
Net Debt @ 168 cr
RoCE ( annualised for Q1 ) @ 13.6 pc
Hospitals business highlights ( only of standalone business ) -
Revenues - 240 vs 216 cr
EBITDA - 58 vs 49 cr
PAT - 30 vs 26 cr
Company’s Hospitals portfolio -
Hospitals - 16 - 11 multi speciality, 05 single speciality
Company owned and operated units - 10
Franchise units - 6 ( FOSM - 4, FOSO - 2 )
Bed capacity @ 2350
Doctors team @ 1150
OPD clinics - 60 Domestic, 23 International
Payor Mix -
Self Pay - 35 pc
Insurance - 41 pc
Govt Schemes - 24 pc
Operational matrix of Shalby Sonar Hospital ( acquired LY ) -
Revenues - 24 vs 20 cr
EBITDA - (-) 0.35 cr - company is confident of turning this around in near future
ARPOB - 79k
Occupancy @ 26 pc
56 pc of revenues generated from international patients
Bed Capacity @ 130 beds
Expertise in Kidney, Liver and Bone marrow transplant
Homecare business clocked a revenue of 3.7 vs 3.6 cr YoY. Patients served @ 7.3k vs 7.6k YoY
Revenues from FOSO hospitals ( franchise owned, Shalby operated ) - 2.6 vs 1.5 cr
Revenues from FOSM hospitals ( franchise owned, Shalby managed ) - 0.75 vs 1.1 cr
Signed up a new hospital under FOSO model @ Rajkot with a bed capacity of 25 beds
Implants business -
Revenues - 26 vs 16 cr
EBITDA - (-) 0.7 cr (-) 0.35 cr ( due front loading of a lot of marketing expenses )
Implants sold @ 3475 vs 1410 pieces
India sales @ 56 pc, US sales @ 44 pc
Company has sharpened its focus on cost cutting wrt their implants business and hiring multiple vendors for supply of similar components
Company is the largest hospital chain in the world in terms of Joint Replacement surgeries performed
Consolidated occupancy rates stood @ 50 pc ( clearly there is a lot of scope for improvement )
Company believes that weakness in homecare business is an aberration. Should see a pick up in the coming Qtrs
Expect Sanar hospital to be EBITDA positive going fwd. Aim to make it PBT positive by end of FY 25 or thereabouts
The Rajkot FOSO Hospital should go live in Q2. A few more Franchise deals are in the pipeline. Company is not disclosing them as yet due competitive reasons
Higher finance costs in Q1 due higher working capital requirements of the implants business and the additional debt taken up for the Sanar acquisition. Higher finance costs will only moderate by next FY once the Implants business stabilises
Disc : holding, biased, not SEBI registered, Concall and results summary posted only for educational purposes
Shalby Ltd -
Q1 FY 25 concall and results highlights -
Revenues - 288 vs 240 cr, up 20 pc
EBITDA - 55 vs 47 cr, up 15 pc
PAT - 15 vs 20 cr ( due higher Interest and Depreciation costs + increased tax rate )
Net Debt @ 168 cr
RoCE ( annualised for Q1 ) @ 13.6 pc
Hospitals business highlights ( only of standalone business ) -
Revenues - 240 vs 216 cr
EBITDA - 58 vs 49 cr
PAT - 30 vs 26 cr
Company’s Hospitals portfolio -
Hospitals - 16 - 11 multi speciality, 05 single speciality
Company owned and operated units - 10
Franchise units - 6 ( FOSM - 4, FOSO - 2 )
Bed capacity @ 2350
Doctors team @ 1150
OPD clinics - 60 Domestic, 23 International
Payor Mix -
Self Pay - 35 pc
Insurance - 41 pc
Govt Schemes - 24 pc
Operational matrix of Shalby Sonar Hospital ( acquired LY ) -
Revenues - 24 vs 20 cr
EBITDA - (-) 0.35 cr - company is confident of turning this around in near future
ARPOB - 79k
Occupancy @ 26 pc
56 pc of revenues generated from international patients
Bed Capacity @ 130 beds
Expertise in Kidney, Liver and Bone marrow transplant
Homecare business clocked a revenue of 3.7 vs 3.6 cr YoY. Patients served @ 7.3k vs 7.6k YoY
Revenues from FOSO hospitals ( franchise owned, Shalby operated ) - 2.6 vs 1.5 cr
Revenues from FOSM hospitals ( franchise owned, Shalby managed ) - 0.75 vs 1.1 cr
Signed up a new hospital under FOSO model @ Rajkot with a bed capacity of 25 beds
Implants business -
Revenues - 26 vs 16 cr
EBITDA - (-) 0.7 cr (-) 0.35 cr ( due front loading of a lot of marketing expenses )
Implants sold @ 3475 vs 1410 pieces
India sales @ 56 pc, US sales @ 44 pc
Company has sharpened its focus on cost cutting wrt their implants business and hiring multiple vendors for supply of similar components
Company is the largest hospital chain in the world in terms of Joint Replacement surgeries performed
Consolidated occupancy rates stood @ 50 pc ( clearly there is a lot of scope for improvement )
Company believes that weakness in homecare business is an aberration. Should see a pick up in the coming Qtrs
Expect Sanar hospital to be EBITDA positive going fwd. Aim to make it PBT positive by end of FY 25 or thereabouts
The Rajkot FOSO Hospital should go live in Q2. A few more Franchise deals are in the pipeline. Company is not disclosing them as yet due competitive reasons
Higher finance costs in Q1 due higher working capital requirements of the implants business and the additional debt taken up for the Sanar acquisition. Higher finance costs will only moderate by next FY once the Implants business stabilises
Disc : holding, biased, not SEBI registered, Concall and results summary posted only for educational purposes
Yes you are right. However the revenue from new KAVACH tenders in unlikely to come in this FY. On the concall they mentioned that after tender announcement Railways takes 6-7 months for awarding the contract. Execution starts after that. So newer tenders will reflect in financials in FY26 only.
Hi Amol, the forecasted revenue of FY25, is excluding any new KAVACH orders? If there is a tender out, the revenue might increase?
Is my interpretation correct?
Any views on OFS by Glenmark?
Personally, I feel that this will remove the overhang of Glenmark balance stake sale and may be long term investors get in around 810 levels.
I am also considering adding more and pyramiding my stake as the margins are amongst the best in category and Mr Yasir leadership will help in decent growth in coming years.
Nirma future plans remain unanswered but seems there will be more clarity incoming quarters.
I am not expert, but i am working marine filed. What I noticed that when major planned maintenance or overhaul is done most of the time we use only OEM products only .
Reson - the failure of machinery due to usage of non OEM products can cause more loss due the failure rather than small cost saving advantage.
That’s why its sticky and long business.
Hi, where can I get a copy of this stock analysis template
Given the kind of of run in the markets its the companies like HDFC Bank give stability to the PF.
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!